Lymphomologist at @IEOUfficiale, Milan
Milano, Italy
Joined August 2014
- Tweets53
- Following154
- Followers46
- Likes170
Caterina Cristinelli retweeted
Ad #ASCO2026 il Prof.@EDerenzini, Direttore della Divisione di Oncoematologia IEO, presenta i risultati dello studio internazionale di fase 1 PRIMAVERA. Lo studio ha valutato una nuova terapia mirata orale, AZD3470, in pazienti con linfoma di Hodgkin.
Safety and efficacy of CD3xCD20 bispecific antibody for the treatment of primary and secondary central nervous system lymphoma patients: A multicentric retrospective study doi.org/10.1182/blood-2025-1…
Caterina Cristinelli retweeted
Original Article: Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia (CLL17 phase 3 trial) nej.md/3KiZKwl
#ASH25 | @ASH_hematology
Empirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in Leukaemia - thelancet.com/journals/lanin…
Caterina Cristinelli retweeted
Antibody-Drug Conjugates and Bispecific Antibodies for
#Lymphoma: Partners of Convenience or a Perfect Match | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO… #lymsm
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Caterina Cristinelli retweeted
Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia ow.ly/R37Q50WnF26 #lymphoidneoplasia
Caterina Cristinelli retweeted
Bispecific antibodies in diffuse large B-cell lymphoma: a new review.
haematologica.org/article/vi…
Caterina Cristinelli retweeted
Glofi escalated ramp-up post-CAR:
- glofi 30 mg by D8
- 46 pts, all prior CAR, 48% relapse >6 mos post CAR
- mPFS 3.8 mos, mOS 14.7 mos
- 9% G2 CRS, 2% G2 ICANS, no G3+
Accelerated ramp-up w/o additional tox. #lymsm #tcellrx
nature.com/articles/s43018-0…
Caterina Cristinelli retweeted
2nd myeloid cancers post CD19 CAR @NGazeau14
- 539 pts, all B-NHL
- 2-yr cumulative risk t-MN: 4.5% (10% at 4 yrs!)
- ⬆️ MCV & high-grade ICANS risk factors for t-MN
- 86% of t-MN had pre-CAR mutations
Important retrospective study for #tcellrx. #lymsm
nature.com/articles/s41375-0…
Caterina Cristinelli retweeted
Just published in @JCO_ASCO the updated @ASCO guidelines on fertility preservation in people with #cancer: a must read for all colleagues involved in cancer care to increase awareness on #oncofertility issues
@OncoAlert @AnnPartridgeMD @oncofertility
Link:
ascopubs.org/doi/10.1200/JCO…
Caterina Cristinelli retweeted
New publication 📝 Results from the phase III SYMPATICO trial published in @TheLancetOncol show ibrutinib-venetoclax vs ibrutinib-placebo improved PFS while maintaining a tolerable safety profile in patients with R/R MCL
👉 loom.ly/zALGy0g
#lymphoma #lymsm #MedNews #MedEd
Caterina Cristinelli retweeted
2nd day of preceptorship on lymphomas today! @HopSaintLouis @muséedesmoulages.
Toxicities of #cartcell , #nuclearmedicine challenges, pharmacological features and more!
Welcome 🇲🇽! @RenataUrsu @laetitiavercellino @c_thieblemont @isabellemadelaine @CCristinelli
Caterina Cristinelli retweeted
So glad to welcome Mexican colleagues for 2025 edition of @HopSaintLouis Preceptorship on lymphomas! Day one of our focus on #cartcells and #bsAbs @c_thieblemont @CCristinelli – at Paris, France
Caterina Cristinelli retweeted
@HopSaintLouis au top 👌
19,25/20. Jamais eu une aussi bonne note de ma vie.
#1 dans la catégorie lymphome-myélome
Cc @c_thieblemont B. Arnulf @Roberta04704608 @CCristinelli @DrAlexisTalbot
Another important step in understanding pathogenesis of CD 🔬is out today :
“Interleukin‐6 transcripts up‐regulation in lymph nodes from unicentric and multicentric Castleman disease” - Lucioni - eJHaem - Wiley Online Library onlinelibrary.wiley.com/doi/…
Caterina Cristinelli retweeted
The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas
ow.ly/CXRr50TkrZB #drugadvances #clinicaltrialsandobservations #immunobiologyandimmunotherapy #lymphoidneoplasia
Caterina Cristinelli retweeted
Today’s #ehaThinkingThursday is on latest recommendations for first-line treatment of Chronic Lymphocytic #Leukemia and they do not involve chemotherapy! Can you fill in A, B & C? Let us know below or swipe for the answer.
See our #CLL program for more: ehaedu.org/CLL_Prog
Caterina Cristinelli retweeted
Jamais simple de revenir de vacances, mais quel bonheur de retrouver @HopSaintLouis et la formidable équipe d’hémato-oncologie!
#lymphome #LLC
Cc @c_thieblemont @Roberta04704608 @CCristinelli
Really beautiful exchange on new therapies in #DLBCL 🇧🇷
Fantastic 2-day discussion on new strategies in DLBCL with colleagues and friends from Brazil! @HopSaintLouis @CancerParisNord @univ_paris_cite
